Plus   Neg

Stock Alert: Vaxart Rises Following Positive Data On COVID-19 Vaccine Program

Shares of Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines, are climbing more than 30% after the company announced that it has achieved positive pre-clinical results for its COVID-19 vaccine candidates. The company said, many of its vaccine candidates achieved immune responses in all tested animals after a single dose.

Vaxart plans to select one or more vaccine candidates for cGMP manufacturing and clinical testing based on the immune response.

In March,Vaxart had entered into an agreement with Emergent BioSolutions for development services to prepare for cGMP production of an oral COVID-19 vaccine.

Emergent is expected to produce bulk cGMP vaccine to initiate a Phase 1 study during the second half of 2020.

VXRT is currently trading at $3.15. It has traded in the range of $0.25- $3.5 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT